Apogenix appoints Peter Willinger as new Chief Financial Officer

>> press release

About Apogenix

Apogenix is an immuno-oncology company focusing on the development of innovative protein therapeutics for the treatment of cancer and other malignant diseases. With a dedicated, highly qualified team, we have built a promising pipeline of drug candidates that target TNFSF-dependent signaling pathways. Apogenix' TNFSF modulators re-establish the body's immune response against tumors and inhibit invasive tumor cell growth.



Our lead drug candidate APG101 has demonstrated a statistically significant efficacy in a controlled phase II trial in recurrent glioblastoma – only six years after the first publication of preclinical data that laid the foundation for the use of APG101 to treat this devastating disease. APG101 is currently being evaluated in a phase I trial for the treatment of myelodysplastic syndromes.



The potent antitumor activity of Apogenix’ TRAIL receptor agonists – APG880 and derivatives – has been demonstrated in numerous preclinical studies. Apogenix has entered into a licensing agreement with a large pharmaceutical company to advance the development of these TRAIL receptor agonists.